- Home
- CLRB vs ALLR Comparison
CLRB vs ALLR Comparison
Compare CLRB & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- ALLR
- Stock Information
- Founded
- CLRB 2002
- ALLR 2004
- Country
- CLRB United States
- ALLR United States
- Employees
- CLRB N/A
- ALLR N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- ALLR Health Care
- Exchange
- CLRB Nasdaq
- ALLR Nasdaq
- Market Cap
- CLRB 14.2M
- ALLR 15.8M
- IPO Year
- CLRB N/A
- ALLR N/A
- Fundamental
- Price
- CLRB $4.98
- ALLR $1.73
- Analyst Decision
- CLRB Hold
- ALLR Strong Buy
- Analyst Count
- CLRB 2
- ALLR 1
- Target Price
- CLRB N/A
- ALLR $9.00
- AVG Volume (30 Days)
- CLRB 154.8K
- ALLR 21.2M
- Earning Date
- CLRB 08-14-2025
- ALLR 08-15-2025
- Dividend Yield
- CLRB N/A
- ALLR N/A
- EPS Growth
- CLRB N/A
- ALLR N/A
- EPS
- CLRB N/A
- ALLR N/A
- Revenue
- CLRB N/A
- ALLR N/A
- Revenue This Year
- CLRB N/A
- ALLR N/A
- Revenue Next Year
- CLRB N/A
- ALLR N/A
- P/E Ratio
- CLRB N/A
- ALLR N/A
- Revenue Growth
- CLRB N/A
- ALLR N/A
- 52 Week Low
- CLRB $4.11
- ALLR $0.61
- 52 Week High
- CLRB $67.50
- ALLR $5.20
- Technical
- Relative Strength Index (RSI)
- CLRB 51.74
- ALLR 73.94
- Support Level
- CLRB $4.43
- ALLR $1.36
- Resistance Level
- CLRB $5.08
- ALLR $1.77
- Average True Range (ATR)
- CLRB 0.40
- ALLR 0.21
- MACD
- CLRB 0.10
- ALLR 0.08
- Stochastic Oscillator
- CLRB 73.11
- ALLR 58.94
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.